logo-loader
viewCarillion

Carillion makes third attempt to woo Balfour shareholders

construction350_53f36ea97d365.jpg

Carillion (LON:CLLN) shares edged lower as a third proposal to merge with sector peer Balfour Beatty (LON:BBY) was laid on the table.

The last gasp offer comes ahead of this Thursday, which is the deadline under takeover rules, after which Carillion would have to wait six months for any further approach.

As expected, it is a sweetened deal, which offers Balfour shareholders 58.268% of the combined company -  up from the previous 56.5%.

Shareholders would also get a cash dividend of 8.5 pence per share.

The new terms value Balfour at £2.1bn (US$3.5 billion).

The pair and the merger plan haven't been out of the news much recently since they revealed in June they were first in talks over the creation of a potential £3bn mega construction firm.

Philip Green, Carillion chairman said today: "Given the scale of the prize for shareholders of both Balfour Beatty and Carillion from a merger of the two companies, the board of Carillion remains committed to moving forward in a constructive and collaborative way with the board and management of Balfour Beatty to create a world-class business and very significant value for the shareholders of both companies"

Balfour shares added 3.87% on Tuesday.

Quick facts: Carillion

Price: 14.2 GBX

LSE:CLLN
Market: LSE
Market Cap: £61.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 11 hours ago

2 min read